BTTC Clinical Trials
Advancing Outcomes for Patients with Brain Tumors
Clinical trials are in-depth medical research studies conducted to understand whether promising approaches to cancer prevention, diagnosis and treatment are safe and effective. BTTC studies are focused on investigating the effectiveness and safety of treatment regimens as well as quality of life involving malignant gliomas, the most common and most aggressive type of adult brain tumors. The two-year survival rate of glioblastoma patients is less than thirty percent, and our hope is to improve those numbers.
Since its inception, the BTTC has experienced unparalleled advancements in the research of alternative treatments of malignant brain tumors. The BTTC has completed a number of clinical trials, and several exciting new trials are in development. Once data from the trials is compiled and results published, we will glean insightful conclusions in our fight against brain cancer.
Open BTTC Clinical Trials
GBM Pembro HSPPC - Newly Diagnosed Glioblastoma Patients Before Surgery
Immunotherapy is the most exciting area of cancer research. Enhancing the patient’s immune response to their cancer has led to important breakthroughs in a variety of cancers including lung cancer and melanoma. However, immune targeting of brain cancer is likely to be much more complicated than other cancers because of the blood-brain barrier that requires that the immune cells penetrate the brain. In addition, immune cells may have more difficulty in recognizing brain tumors because of the blood-brain barrier. This state-of-the-art study will be the first to evaluate the combination of a personalized cancer vaccine made from the patient’s own tumor tissue (HSPPC-96) and PD-1 inhibition (Pembrolizumab) in newly diagnosed GBM. The combination of the HSPCC-96 vaccine and Pembrolizumab may synergistically result in an increase in tumor-specific immune response. Learn more about this trial...
|View Pembro Flyer|
Everolimus/Sorafenib Study - Patients With Recurrent High-Grade Gliomas
This study will evaluate the occurrence of symptoms and their relations to disease progression, as well as the tolerance to treatment regimen. A phase I-II trial everolimus and sorafenib in patients with recurrent high-grade gliomas. Learn more about this trial...
Not Yet Recruiting BTTC Clinical Trials
Pazopanib/Topotecan Study - Patients With Recurrent Glioblastoma
The study’s primary objective is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied. A phase II trial of pazopanib and topotecan in adult patients with recurrent glioblastoma. Learn more about this trial...
Completed BTTC Clinical Trials
Bevacizumab/Vorinostat Study - Patients With Recurrent Glioblastoma
This study evaluated the occurrence of symptoms and their relations to disease progression, as well as the tolerance to the treatment regimen. Phase I/II adaptive randomized trial of bevacizumab versus bevacizumab plus vorinostat in adults with recurrent glioblastoma. Learn more about this trial...
Bevacizumab (Avastin)/Tarceva Study - Newly Diagnosed Malignant Glioma Patients
The study evaluated the effects and determined overall survival rates of newly diagnosed malignant glioma patients when administering a combination of bevacizumab (Avastin) and erlotinib (Tarceva) following the completion of radiation therapy with temozolomide (Temodar). Learn more about this trial...
Temodar Combination Study - Newly Diagnosed Glioblastoma Patients
The study determined if temozolomide (Temodar) administered alone or in combination with thalidomide (Thalomid™), isotretinion (Accutane) and/or celecoxib (Celebrex) was effective in the continued treatment of newly diagnosed glioblastoma patients who already had incurred radiation therapy. Also, the toxicity of this adjuvant treatment was studied. Learn more about this trial...
Interested in participating in a BTTC clinical trial?
Contact the BTTC Coordinating Center: e-mail NCI_BTTC@mail.nih.gov or call (240) 760-6060.